Compare EM & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EM | CCCC |
|---|---|---|
| Founded | 2017 | 2015 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 291.6M | 240.3M |
| IPO Year | 2021 | 2020 |
| Metric | EM | CCCC |
|---|---|---|
| Price | $1.14 | $2.12 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $1.25 | ★ $7.25 |
| AVG Volume (30 Days) | 544.0K | ★ 1.7M |
| Earning Date | 03-05-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $259,541,587.00 | $30,108,000.00 |
| Revenue This Year | $3.30 | N/A |
| Revenue Next Year | $5.26 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.99 | $1.09 |
| 52 Week High | $1.46 | $4.03 |
| Indicator | EM | CCCC |
|---|---|---|
| Relative Strength Index (RSI) | 32.67 | 46.02 |
| Support Level | $1.13 | $2.02 |
| Resistance Level | $1.19 | $2.47 |
| Average True Range (ATR) | 0.04 | 0.14 |
| MACD | 0.01 | 0.03 |
| Stochastic Oscillator | 72.71 | 41.67 |
Smart Share Global Ltd is a consumer tech company providing mobile device charging services through an extensive online and offline network in China. It provides service through power banks, placed in POIs operated by location partners, such as entertainment venues, restaurants, shopping centers, hotels, transportation hubs, and public spaces. Geographically, the company generates revenue from the PRC. The company has two segments, the mobile device charging segment and the PV business segment. The company generates the majority of its revenue from the mobile device charging segment.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.